Tim Mason – CEO – Eagle Mountain Mining Limited (ASX:EM2), is a copper focused exploration and development Company with a key objective of becoming a low emission producer at its high-grade Oracle Ridge project in Arizona, USA, to supply the rapidly growing green energy market.
Copyright 2024 – Finance News Network
11 Dec 2020 - Novatti Group Limited (ASX:NOV) Managing Director Peter Cook discusses the company's strategy of partnering with Tier 1 companies, including Ripple, Google Pay and Samsung Pay.
19 Feb 2020 - BluGlass (ASX:BLG) Managing Director, Giles Bourne talks about the opportunities that laser diodes represent for the company, following the Photonics West Conference.
16 Dec 2019 - Botanix Pharmaceuticals Limited (ASX:BOT) Founder Matthew Callahan talks about the company's Phase 2 US trial results for severe acne, plans for its Phase 3 trails, including FDA input, its Phase 2 atopic dermatitis study, and what investors can expect over the next 6 months.
26 Sep 2024 - QX Resources Limited (ASX:QXR) Managing Director Steve Promnitz discusses the company's renegotiation of the option agreement for the Liberty Lithium Brine Project, which now allows for opportunities in two additional lithium projects in Nevada and Utah. He highlights the strategic importance of being positioned in the US lithium market amid growing demand for battery minerals.
14 Aug 2019 - ALE Property Group Limited (ASX:LEP) Managing Director, Andrew Wilkinson discusses the company’s FY19 results, valuations and rent reviews
29 Feb 2024 - Mitch Thomas - CFO - Latin Resources (ASX:LRS) is exploring and developing sustainable minerals in Australia and Latin America to provide the planet with environmentally friendly products.
06 Mar 2024 - Arrow Minerals (ASX:AMD) Managing Director David Flanagan provides introduction to the company, discussing the companies Simandou North Iron Project in West Africa.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.